Join

Compare · NUWE vs SLNO

NUWE vs SLNO

Side-by-side comparison of Nuwellis Inc. (NUWE) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NUWE and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • SLNO is the larger of the two at $2.76B, about 2159.1x NUWE ($1.3M).
  • Over the past year, NUWE is down 98.5% and SLNO is down 31.5% - SLNO leads by 67.0 points.
  • SLNO has been more active in the news (42 items in the past 4 weeks vs 8 for NUWE).
  • SLNO has more recent analyst coverage (12 ratings vs 1 for NUWE).
PerformanceNUWE-95.71%SLNO-31.50%
2025-06-20+0.00%2026-06-03
MetricNUWESLNO
Company
Nuwellis Inc.
Soleno Therapeutics Inc.
Price
$0.49-17.40%
$53.02+0.08%
Market cap
$1.3M
$2.76B
1M return
-56.65%
+0.76%
1Y return
-98.50%
-31.50%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NASDAQ
IPO
2014
News (4w)
8
42
Recent ratings
1
12
NUWE

Nuwellis Inc.

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

SLNO

Soleno Therapeutics Inc.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Latest NUWE

Latest SLNO